| Literature DB >> 31687392 |
Yuxuan Hong1,2,3, Yingxian Cheng1,2,3, Yanjuan Li1,2,3, Xiaowen Li1,2,3, Zutao Zhou1,2,3, Deshi Shi1,2,3, Zili Li1,2,3, Yuncai Xiao1,2,3.
Abstract
Probiotics can promote the health and growth performance of animals through modulation of intestinal microbiota. When used as a feed additive, they have the potential to minimize or abolish the use of antibiotics. In this study, we investigated the effect of the probiotic strain Bacillus amyloliquefaciens TL on the growth performance and cecum microflora composition in Cobb 500 broiler chickens. In total, 180 broilers were randomly divided into three groups-each group comprised 4 pens, and each pen contained 15 chickens. The three groups were fed either a control diet, or a diet supplemented with either the antibiotic chlortetracycline or B. amyloliquefaciens TL. Broilers were weighed, and cecum contents were collected on days 7, 14, 21, and 35, respectively. The broilers in both the antibiotic and probiotic groups exhibited significant weight gain compared with controls, exhibiting increases of 16.02% and 13.40%, respectively, after 35 days (P < 0.01). Similarly, the feed conversion ratio (FCR, 1-35 days) of broilers in the chlortetracycline and B. amyloliquefaciens TL groups was lower than that of the controls. HiSeq high-throughput sequencing of 16S rRNA of the cecal microbiota was performed on days 7, 14, 21, and 35, respectively. The Firmicutes/Bacteroidetes ratio was higher in the chlortetracycline and B. amyloliquefaciens TL groups than in the control group on days 14, 21, and 35, and especially on day 21. The prevalence of genera Oscillospira, Ruminococcus, Butyricicoccus, and Faecalibacterium (Firmicutes) was higher in the antibiotic and probiotic groups, while that of Bacteroides, Parabacteroides (Bacteroidetes), and Lactobacillus was higher in the control group. In this study, the changes in the microbiota of the probiotic group were similar to those in the antibiotic group. These results suggest that the probiotic strain B. amyloliquefaciens TL can modulate the cecal microbiota of broilers similar to chlortetracycline.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31687392 PMCID: PMC6794981 DOI: 10.1155/2019/5431354
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Growth performance in broiler chickens.
| Parameters | Treatment |
| |||||
|---|---|---|---|---|---|---|---|
| C | A | P | P vs. C | A vs. C | P vs. A | ||
| (Mean ± SD) | (Mean ± SD) | (Mean ± SD) | |||||
| Body weight (g) | 7 days | 147.48 ± 11.08 | 146.50 ± 9.09 | 157.35 ± 8.58 | n.s. | n.s. |
|
| 14 days | 499.75 ± 20.67 | 509.50 ± 46.20 | 532.50 ± 24.09 | n.s. | n.s. | n.s. | |
| 21 days | 858.62 ± 30.74 | 999.75 ± 64.47 | 1076.12 ± 98.48 |
|
|
| |
| 35 days | 1901.38 ± 76.36 | 2206.00 ± 263.57 | 2156.12 ± 198.61 | n.s. |
| n.s. | |
|
| |||||||
| Daily weight gain (g) | 0–7 days | 15.23 ± 1.38 | 15.22 ± 1.15 | 16.82 ± 1.08 |
| n.s. |
|
| 7–14 days | 50.32 ± 1.51 | 51.86 ± 5.35 | 53.59 ± 2.33 | n.s. | n.s. | n.s. | |
| 14–21 days | 51.27 ± 1.74 | 70.04 ± 3.01 | 77.66 ± 10.74 |
|
|
| |
| 21–35 days | 80.21 ± 3.72 | 92.79 ± 16.24 | 83.08 ± 9.23 | n.s. |
| n.s. | |
|
| |||||||
| FCR (1–35 days) | 2.02 | 1.63 | 1.62 | ||||
n.s. means not significant (P > 0.05); significant (P < 0.05); extreme significant (P < 0.01). C = control group; A = chlortetracycline group; P = Bacillus amyloliquefaciens TL group; FCR: feed conversion ratio.
Figure 1Differences in bacterial community diversity, richness, and cecum microfloral structure following treatment with probiotics (“P”), antibiotics (“A”), or no treatment (“C”). (a) Bar graph showing the Chao1. (b) Shannon index for all treatment groups on days 7, 14, 21, or 35 (P < 0.05; P < 0.01).
Figure 2(a) Principal coordinate analysis of the unweighted UniFrac distance metric for all treatment groups on the indicated days. The relative abundance of various phyla is indicated by colored bars. (b) NMDS analysis of the cecal microflora of the indicated groups on the indicated days. Closer samples have more similar species composition (P < 0.05; P < 0.01).
Figure 3(a) Relative abundance of Firmicutes and Bacteroidetes in the antibiotic (“A”), probiotic (“P”), and control (“C”) groups at days 7, 14, 21, and 35 is shown. (P < 0.05; P < 0.01). (b) The prevalence of Firmicutes and Bacteroidetes (phylum level) and Bacteroides (genus level) in the antibiotic and probiotic groups and the control group as time progressed.
Differences in the abundance of the eight bacterial genera among the control, antibiotic, and probiotic groups, as determined on day 7 (n = 4).
| Taxa | Relative abundance | ||
|---|---|---|---|
| Genus | C | P | A |
| (Mean% ± SD) | (Mean% ± SD) | (Mean% ± SD) | |
|
| 5.99 ± 0.026 | 7.57 ± 0.022 | 8.81 ± 0.034 |
|
| 3.56 ± 0.002 | 4.11 ± 0.003 | 4.06 ± 0.003 |
|
| 1.03 ± 0.007 | 0.429 ± 0.002 | 1.82 ± 0.009 |
|
| 2.48 ± 0.013 | 1.81 ± 0.004 | 1.52 ± 0.003 |
|
| 1.17 ± 0.003 | 1.26 ± 0.001 | 1.46 ± 0.004 |
|
| 1.60 ± 0.007 | 1.03 ± 0.001 | 1.23 ± 0.002 |
|
| 1.58 ± 0.002 | 1.59 ± 0.002 | 1.04 ± 0.002 |
|
| 1.09 ± 0.004 | 0.85 ± 0.002 | 1.10 ± 0.001 |
None of the comparisons have significant difference on the same line based on the P value. C = control group; A = chlortetracycline group; P = Bacillus amyloliquefaciens TL group.
Differences in the abundance of nine bacterial genera among the control, antibiotic, and probiotic groups, as determined on day 14 (n = 7).
| Taxa | Relative abundance |
| ||||
|---|---|---|---|---|---|---|
| Genera | C | P | A | P vs. C | A vs. C | P vs. A |
| (Mean% ± SD) | (Mean% ± SD) | (Mean% ± SD) | ||||
|
| 8.3 ± 0.024 | 15.25 ± 0.039 | 14.57 ± 0.039 | n.s. | n.s. | n.s. |
|
| 2.94 ± 0.002 | 3.79 ± 0.003 | 4.09 ± 0.005 |
|
| n.s. |
|
| 1.88 ± 0.005 | 2.29 ± 0.002 | 1.75 ± 0.003 | n.s. | n.s. | n.s. |
|
| 0.60 ± 0.001 | 1.13 ± 0.000 | 1.30 ± 0.001 |
|
| n.s. |
|
| 1.45 ± 0.002 | 1.37 ± 0.002 | 1.48 ± 0.002 | n.s. | n.s. | n.s. |
|
| 3.92 ± 0.008 | 0.32 ± 0.003 | 0.31 ± 0.001 |
|
| n.s. |
|
| 0.68 ± 0.001 | 0.55 ± 0.002 | 1.08 ± 0.002 | n.s. | n.s. | n.s. |
|
| 1.07 ± 0.002 | 1.09 ± 0.002 | 0.96 ± 0.001 | n.s. | n.s. | n.s. |
|
| 1.34 ± 0.003 | 0.020 ± 0.000 | 0.0015 ± 0.000 |
|
| n.s. |
n.s. means not significant (P > 0.05); significant (P < 0.05). C = control group; A = chlortetracycline group; P = Bacillus amyloliquefaciens TL group.
Difference in the abundance of nine bacterial genera among the control, antibiotic, and probiotic groups, as determined on day 21 (in the antibiotic group, n = 7; in the probiotic and control groups, n = 8).
| Taxa | Relative abundance |
| ||||
|---|---|---|---|---|---|---|
| Genera | C | P | A | P vs. C | A vs. C | P vs. A |
| (Mean% ± SD) | (Mean% ± SD) | (Mean% ± SD) | ||||
|
| 7.44 ± 0.010 | 6.61 ± 0.011 | 7.56 ± 0.015 | n.s. | n.s. | n.s. |
|
| 20.24 ± 0.016 | 2.55 ± 0.018 | 1.02 ± 0.005 |
|
| n.s. |
|
| 1.34 ± 0.002 | 3.19 ± 0.004 | 2.65 ± 0.001 |
|
| n.s. |
|
| 2.82 ± 0.008 | 0.0097 ± 0.010 | 0.013 ± 0.000 |
|
| n.s. |
|
| 0.82 ± 0.000 | 1.62 ± 0.002 | 1.69 ± 0.003 |
|
| n.s. |
|
| 0.62 ± 0.002 | 1.74 ± 0.002 | 1.51 ± 0.002 |
|
| n.s. |
|
| 1.43 ± 0.005 | 0.117 ± 0.001 | 0.0125 ± 0.000 |
|
|
|
|
| 0.09 ± 0.000 | 1.21 ± 0.004 | 1.07 ± 0.004 |
|
| n.s. |
|
| 5.11 ± 0.010 | 0.36 ± 0.002 | 0.906 ± 0.002 |
|
| n.s. |
n.s. means not significant (P > 0.05); significant (P < 0.05). C = control group; A = chlortetracycline group; P = Bacillus amyloliquefaciens TL group.
Difference in the abundance of nine bacterial genera among the control, antibiotic, and probiotic groups, as determined on day 35 (n = 8).
| Taxa | Relative abundance |
| ||||
|---|---|---|---|---|---|---|
| Genera | C | P | A | P vs. C | A vs. C | P vs. A |
| (Mean% ± SD) | (Mean% ± SD) | (Mean% ± SD) | ||||
|
| 3.29 ± 0.005 | 8.34 ± 0.015 | 9.25 ± 0.020 |
|
| n.s. |
|
| 9.72 ± 0.015 | 5.93 ± 0.015 | 7.77 ± 0.016 | n.s. | n.s. | n.s. |
|
| 5.20 ± 0.005 | 4.31 ± 0.002 | 6.91 ± 0.022 | n.s. | n.s. | n.s. |
|
| 2.16 ± 0.002 | 2.55 ± 0.002 | 2.17 ± 0.002 | n.s. | n.s. | n.s. |
|
| 1.24 ± 0.001 | 1.24 ± 0.001 | 1.50 ± 0.000 | n.s. | n.s. | n.s. |
|
| 7.06 ± 0.003 | 1.49 ± 0.006 | 0.74 ± 0.003 |
|
| n.s. |
|
| 1.815 ± 0.007 | 0.375 ± 0.003 | 0.127 ± 0.001 |
|
| n.s. |
|
| 0.84 ± 0.007 | 1.88 ± 0.011 | 0.16 ± 0.000 | n.s. |
|
|
|
| 1.30 ± 0.001 | 0.174 ± 0.000 | 0.32 ± 0.001 |
|
| n.s. |
n.s. means not significant (P > 0.05); significant (P < 0.05). C = control group; A = chlortetracycline group; P = Bacillus amyloliquefaciens TL group.